BREZTRI is administered as 2 inhalations, twice daily1:

Each inhalation delivers a combination of 160 mcg budesonide, 9 mcg glycopyrrolate, and 4.8 mcg formoterol fumarate1

BREZTRI Dosing Information
BREZTRI Dosing Information

Patients should not take more than two inhalations twice daily.1 

After inhalation, the patient should rinse their mouth with water without swallowing.1 

Priming BREZTRI AEROSPHERE is essential to ensure appropriate drug content in each actuation.1 

BREZTRI AEROSPHERE contains 28 or 120 inhalations per canister.1

  • BREZTRI should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors and tricyclic antidepressants, as these may potentiate the effect of formoterol fumarate on the cardiovascular system
  • BREZTRI should be administered with caution to patients being treated with:
    • Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)
    • Adrenergic drugs (may potentiate effects of formoterol fumarate)
    • Xanthine derivatives, steroids, or non-potassium sparing diuretics (may potentiate hypokalemia and/or ECG changes)
    • Beta-blockers (may block bronchodilatory effects of beta-agonists and produce severe bronchospasm)
    • Anticholinergic-containing drugs (may interact additively). Avoid use with BREZTRI
  • Use BREZTRI with caution in patients with hepatic impairment, as budesonide and formoterol fumarate systemic exposure may increase. Patients with severe hepatic disease should be closely monitored